2 scoops is one serve (10g)
A Media Snippet accompanying this announcement is available by clicking on this link
A: According to published clinical trial data for FDA-approved medications: Wegovy (semaglutide 2.4 mg): Average 15% body weight loss at 68 weeks (approximately 33 pounds for 220-pound individual) Zepbound (tirzepatide 15 mg): Average 20% body weight loss at 72 weeks (approximately 44 pounds for 220-pound individual) Critical Context : These represent average results from controlled clinical trials where participants also followed reduced-calorie diets and increased physical activity
Unlike the SUSTAIN-6 study, this study excluded any patients who had pre-existing proliferative diabetic retinopathy (PDR) prior to initiation of tirzepatide and matched patients with their baseline level of DR or DME
Similar content being viewed by others Introduction Obesity, a complex chronic condition caused by a range of biological, behavioral, and environmental factors, poses a major global public health challenge [1], affecting nearly 890 million people worldwide [2] and significantly contributing to cardio-renal-metabolic disease morbidity and mortality [3]
The new doctor said, listen, there is this new drug out now for weight loss called semaglutide
